Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia

International Journal of Molecular Sciences(2020)10.3390/ijms22010020Source: DataRank Database

The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia is a research paper published in International Journal of Molecular Sciences (2020). On theSindex it has a DataRank of 0. It has been cited 11 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access11 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.66)OA: goldTopics (69)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Omar S. Mabrouk ORCID,Lajos Szabó,Andrew J. Flores ORCID,Kate L. Parent,Jean M. Bidlack ORCID

Live enrichment

PubMed:33374986 PMC:PMC7792611 OpenAlex:https://openalex.org/W3114943711

Michael J. Fox Foundation for Parkinson's Research

Grant: No number

National Institute on Drug Abuse

Grant: R43DA026653 and R44 DA026653

NIDA NIH HHS

Grant: T32 DA007268

National Institutes of Health

Grant: 1R43DA026653-01A1

Novel Glycosylated Delta Opioid Receptor Agonists for Chronic Inflammatory Pain

FWCI

0.66

Citation Percentile

0.6%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/1422-0067/22/1/20/pdf?version=1608635348

publisherhttps://www.mdpi.com/1422-0067/22/1/20/pdf?version=1608635348

publisherhttps://www.mdpi.com/1422-0067/22/1/20/pdf

journalhttps://doi.org/10.3390/ijms22010020

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33374986

Fields of Study

Neuropeptides and Animal PhysiologyNeurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology Research03 medical and health sciences0302 clinical medicineAnalgesics, OpioidAnimalsCorpus StriatumDisease Models, AnimalDizocilpine MaleateDyskinesia, Drug-InducedGlycopeptidesLevodopaMaleMotor ActivityNeuroprotective AgentsParkinson Disease, SecondaryRats, Sprague-DawleyReceptors, Opioid, delta

MeSH Terms

Analgesics, OpioidAnimalsCorpus StriatumDisease Models, AnimalDyskinesia, Drug-InducedGlycopeptidesLevodopaMaleMotor ActivityParkinson Disease, SecondaryDizocilpine MaleateRats, Sprague-DawleyReceptors, Opioid, deltaNeuroprotective Agents

Keywords

LevodopaDyskinesiaPharmacologyOpioidChemistryMicrodialysisReceptor antagonistAntagonistGlycopeptideOpioid receptorOpioid peptideParkinson's diseaseAnesthesiaMedicineReceptorDopamineInternal medicineBiochemistryDiseaseBasal GangliaL-dopaParkinson’s DiseaseMaleDyskinesia, Drug-InducedGlycopeptidesMotor ActivityArticleCorpus StriatumAnalgesics, OpioidRats, Sprague-DawleyDisease Models, AnimalNeuroprotective AgentsReceptors, Opioid, deltaAnimalsDizocilpine MaleateParkinson Disease, Secondary

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being